New Macrocyclic Drug Templates That Mimic Protein Structures for Antiviral Applications

Novel macrocyclic amino acids that lock peptides into beta-strand conformations were developed as protease inhibitor templates, with applications in antiviral drug design against HIV and HCV.

Glenn, Matthew P et al.·Journal of medicinal chemistry·2002·Preliminary Evidencein-vitro
RPEP-00730In VitroPreliminary Evidence2002RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Novel macrocyclic amino acids that constrain peptides into beta-strand conformations were developed as protease inhibitor templates, showing application in antiviral drug design against HIV and HCV proteases.

Key Numbers

How They Did This

In-vitro medicinal chemistry study. Macrocyclic amino acids designed, synthesized, and incorporated into protease inhibitor scaffolds. Tested against viral proteases.

Why This Research Matters

Converting flexible peptides into rigid macrocyclic drugs improves their potency, selectivity, and oral bioavailability — key challenges in antiviral peptide drug development.

The Bigger Picture

Macrocyclic drug design is one of pharmaceutical chemistry's most productive strategies for creating peptide-inspired drugs. These building blocks expand the toolkit for targeting viral and other proteases.

What This Study Doesn't Tell Us

In-vitro design and testing. In-vivo pharmacology not demonstrated. The specific potency against viral proteases was not detailed.

Questions This Raises

  • ?Can these macrocyclic templates achieve oral bioavailability?
  • ?How do they compare to existing protease inhibitors?
  • ?Could the approach be applied to other protease-driven diseases?

Trust & Context

Key Stat:
Shape-locked drugs Macrocyclic constraints force peptides into the exact beta-strand shape needed for potent protease inhibition — precision drug engineering
Evidence Grade:
Preliminary medicinal chemistry evidence with novel building block design and protease targeting, limited by early-stage development.
Study Age:
Published in 2002. Macrocyclic protease inhibitors have become mainstream in drug design, with several macrocyclic drugs now approved for HIV and HCV.
Original Title:
Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.
Published In:
Journal of medicinal chemistry, 45(2), 371-81 (2002)
Database ID:
RPEP-00730

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What are macrocyclic drugs?

Drugs with ring-shaped molecular structures that lock the molecule into the ideal shape for binding its target. This rigidity makes them more potent and stable than their flexible counterparts.

Are these used for viral infections?

Yes, this approach has been validated. Several approved antiviral drugs now use macrocyclic structures to inhibit viral proteases, including treatments for HIV and hepatitis C.

Read More on RethinkPeptides

Cite This Study

RPEP-00730·https://rethinkpeptides.com/research/RPEP-00730

APA

Glenn, Matthew P; Pattenden, Leonard K; Reid, Robert C; Tyssen, David P; Tyndall, Joel D A; Birch, Christopher J; Fairlie, David P. (2002). Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.. Journal of medicinal chemistry, 45(2), 371-81.

MLA

Glenn, Matthew P, et al. "Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.." Journal of medicinal chemistry, 2002.

RethinkPeptides

RethinkPeptides Research Database. "Beta-strand mimicking macrocyclic amino acids: templates for..." RPEP-00730. Retrieved from https://rethinkpeptides.com/research/glenn-2002-betastrand-mimicking-macrocyclic-amino

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.